Effect of a catechol-O-methyl transferase inhibitor, U-0521, with levodopa administration.
D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects; D001921:Brain / Q000187:drug effects / Q000378:metabolism; D065098:Catechol O-Methyltransferase Inhibitors; D004295:Dihydroxyphenylalanine / Q000378:metabolism; D004298:Dopamine / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D006719:Homovanillic Acid / Q000378:metabolism; D007980:Levodopa / Q000494:pharmacology*; D008297:Male; D008750:Methyldopa / Q000378:metabolism; D011427:Propiophenones / Q000494:pharmacology*; D051381:Rats; D013997:Time Factors
D065098:Catechol O-Methyltransferase Inhibitors; D011427:Propiophenones; D007980:Levodopa; C006104:U 0521; D008750:Methyldopa; D004295:Dihydroxyphenylalanine; D004298:Dopamine; D006719:Homovanillic Acid